• 1
    Roehrborn CG, McConnell JD, Lieber M et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53: 473480.
  • 2
    McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 2003; 349: 23872398.
  • 3
    Roehrborn CG, Siami P, Barkin J et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 2010; 57: 123131.
  • 4
    Roehrborn CG, Barkin J, Siami P et al. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int. 2011; 107: 946954.
  • 5
    Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J. Urol. 1993; 150: 8589.
  • 6
    Sarma AV, Jacobsen SJ, Girman CJ et al. Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men. J. Urol. 2002; 168: 14461452.
  • 7
    Lieber MM, Rhodes T, Jacobson DJ et al. Natural history of benign prostatic enlargement: long-term longitudinal population-based study of prostate volume doubling times. BJU Int. 2009; 105: 214219.
  • 8
    Bosch JL, Tilling K, Bohnen AM, Bangma CH, Donovan JL. Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: prediction of future prostate volume in individual men. Prostate 2007; 67: 18161824.
  • 9
    Bosch JL, Bangma CH, Groeneveld FP, Bohnen AM. The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur. Urol. 2008; 53: 819825; discussion 825–7.
  • 10
    Masumori N, Tsukamoto T, Kumamoto Y et al. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community based studies in 2 countries. J. Urol. 1996; 155: 13241327.
  • 11
    Tsukamoto T, Kumamoto Y, Masumori N et al. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J. Urol. 1995; 154: 391395.
  • 12
    Sagnier PP, Girman CJ, Garraway M et al. International comparison of the community prevalence of symptoms of prostatism in four countries. Eur. Urol. 1996; 29: 1520.
  • 13
    Masumori N, Tsukamoto T, Rhodes T, Girman CJ. Natural history of lower urinary tract symptoms in men – result of a longitudinal community-based study in Japan. Urology 2003; 61: 956960.
  • 14
    Fukuta F, Masumori N, Mori M, Tsukamoto T. Internal prostatic architecture on transrectal ultrasonography predicts future prostatic growth: natural history of prostatic hyperplasia in a 15-year longitudinal community-based study. Prostate 2011; 71: 597603.
  • 15
    Fukuta F, Masumori N, Mori M, Tsukamoto T. Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study. BJU Int. 2012; 110: 10231029.
  • 16
    Jacobsen SJ, Jacobson DJ, Girman CJ et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J. Urol. 1999; 162: 13011306.
  • 17
    Masumori N, Tsukamoto T, Kumamoto Y et al. Age-related differences in internal prostatic architecture on transrectal ultrasonography: results of a community based survey in Japan. J. Urol. 1997; 157: 17181722.
  • 18
    Oesterling JE, Kumamoto Y, Tsukamoto T et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br. J. Urol. 1995; 75: 347353.
  • 19
    Fukuta F, Masumori N, Mori M, Tsukamoto T. Prediction of treatment for benign prostatic hyperplasia in the future: results from a 15-year longitudinal community-based study in Shimamaki-mura, Hokkaido. Nihon Hainyokino Gakkaishi 2009; 20: 312316. (In Japanese.)
  • 20
    Roehrborn CG, McConnell J, Bonilla J et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J. Urol. 2000; 163: 1320.
  • 21
    Crawford ED, Wilson SS, McConnell JD et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J. Urol. 2006; 175: 14221426.
  • 22
    Gupta A, Aragaki C, Gotoh M et al. Relationship between prostate specific antigen and indexes of prostate volume in Japanese men. J. Urol. 2005; 173: 503506.